CJC-1295 vs HGH 191AA
Side-by-Side Comparison
| Attribute | Cjc 1295 | Hgh 191aa |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | HGH 191AA binds to the growth hormone receptor (GHR) on target cells, triggering JAK2-STAT5 signaling, which drives transcription of IGF-1 and other growth factors. |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Not approved for human use | FDA-approved (multiple indications). Numerous brand-name products available worldwide. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Common: injection site reactions, fluid retention, joint pain/stiffness, carpal tunnel syndrome; Metabolic: insulin resistance, hyperglycemia (dose-dependent), may precipitate diabetes |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 0.15-2 mg per injection (0.5-6 IU) |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~22,124 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~3-5 hours (SC) |
Overview
CJC-1295 and HGH 191AA are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
HGH 191AA — Mechanism & Evidence
HGH 191AA refers to recombinant human growth hormone (somatropin) — a 191-amino acid, single-chain polypeptide (MW ~22,124 g/mol) identical in sequence to endogenous pituitary growth hormone. It is FDA-approved for growth hormone deficiency in children and adults, Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, and HIV-associated wasting. In the peptide community, "191AA" distinguishes legitimate somatropin from the older 192-amino acid variant (somatrem, which had an extra methionine and higher immunogenicity).
Key claims: Treats growth hormone deficiency; Improves body composition in GH-deficient adults; Anti-aging and rejuvenation effects in healthy elderly.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
HGH 191AA is also researched for: Anti-Aging & Longevity.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
HGH 191AA: Common: injection site reactions, fluid retention, joint pain/stiffness, carpal tunnel syndrome Metabolic: insulin resistance, hyperglycemia (dose-dependent), may precipitate diabetes Endocrine: gynecomastia, hypothyroidism (may unmask central hypothyroidism)
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.